Business Wire

NTHU

22.9.2022 11:01:35 CEST | Business Wire | Press release

Share
Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan

On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one MRT station away from the site where the Hospital will be built.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At the opening ceremony (right to left): NTHU senior vice presidents Tai Nyan-hwa and Lyu Ping-chiang, NTHU president W. John Kao, Taoyuan City mayor Cheng Wen-tsan, former NTHU president Hocheng Hong, Taoyuan Metro chairman Liu Kun-I, and Taoyuan Aerotropolis chairman Chen Si-jhen. (Photo: National Tsing Hua University)

NTHU and the Taoyuan City Government have already signed a letter of intent outlining their plan to jointly establish a world-class medical center that will serve the local community; the plan also includes assistance in the training of bilingual teachers and support for science education and experimental education at Taoyuan’s kindergartens, primary, and secondary schools.

The Preparatory Office was officially inaugurated by Taoyuan City mayor Cheng Wen-tsan and NTHU president W. John Kao.

Mayor Cheng has played a key role in the early stages of the Hospital project. He pointed out that Taiwan is good at both electronics and medical care, both of which are taught at NTHU, and that’s why he has been such a staunch supporter of NTHU through all the difficulties which have arisen in the planning stage.

Cheng emphasized that it will take only ten minutes for an ambulance to go from the Taoyuan International Airport to the emergency room at the new hospital; and that in addition to cosmetic surgery and health examinations, the Hospital will also provide critical care and boron neutron capture therapy (BNCT).

Moreover, the Hospital is expected to become a leading center for the development of advanced cell regeneration technology.

President Kao said that this is a very important day for NTHU, in that the school has long had its sights set on medical education, and now the dream has finally come true, noting that “Today is a new milestone in this 50-kilometer journey from NTHU to Taoyuan, which has been going on for some 66 years.”

Kao also noted that this year could be seen as the “year of medicine” at NTHU, since the first batch of medical students has recently been enrolled.

The Hospital will be located near the Hengshan Station (A16) of the Airport MRT line, on a parcel of land provided by Taoyuan City. The size of the parcel is 7.2 hectares, of which 5 hectares will be used for the Hospital itself, while the remaining 2.2 hectares will be used for the affiliated teaching and research facilities.

NTHU senior vice president Lyu Ping-chiang said that the BOT agreement will be finalized by the end of this year, and that construction will start next year, soon after the parcel is transferred. The Hospital is expected to be completed by the end of 2027 and opened in 2028.

The Hospital will initially have 200 general acute care beds, plus an intensive care unit, a respiratory care unit, negative pressure isolation rooms, and a psychiatric unit for both inpatients and outpatients, all of which will be gradually expanded over a number of years to reach a total capacity of 910 beds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release

All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of

Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release

New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye